Clinical Trials Logo

Colo-rectal Cancer clinical trials

View clinical trials related to Colo-rectal Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06444542 Not yet recruiting - Colo-rectal Cancer Clinical Trials

Understanding Patient Preference on Colorectal Cancer Screening Options-PSU

U-Screen
Start date: May 25, 2024
Phase:
Study type: Observational

There are significant barriers to colorectal cancer screening within underserved populations due to the cost, accessibility, and acceptability of screening methods. Patient-friendly approaches that minimize stress and discomfort for the patient are needed to enhance screening compliance and achieve an early diagnosis. The primary aim of this study is to examine whether the availability of a blood-based screening option, which can be done at the point of service and is familiar to patients, will improve patient compliance to recommended CRC screening

NCT ID: NCT06332274 Not yet recruiting - Cancer Clinical Trials

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

UMBRELLA
Start date: May 2024
Phase: Phase 3
Study type: Interventional

Numerous studies have shown that even when imaging does not reveal the presence of cancer cells, traces of tumor DNA (i.e. originating from cancer cells) can be detected in the blood of certain patients: this is called molecular residual disease (MRD). When such traces are detected (we speak of MRD+ status), the risk of relapse is much higher than when there is no circulating tumor DNA (MRD - status). Given the success of immunotherapy in treating patients with metastatic disease in a variety of tumor types, there is enormous enthusiasm for expanding the use of immunotherapy to people with cancer at an early stage. UMBRELLA is a biology-driven trial designed to study the impact of systemic treatment with tislelizumab monotherapy after detection of MRD+ status after completion of surgery and perioperative treatments in patients with cancer of a solid tumor. Residual disease (MRD) will be determined by optimized detection and precise monitoring of circulating tumor DNA, enabling early detection of recurrence and disease monitoring, including in patients without MRD [MRD(-)].

NCT ID: NCT06218888 Not yet recruiting - Colo-rectal Cancer Clinical Trials

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

To explore the Efficacy and Safety of Tislelizumab combined with fruquintinib and Chidamide in the treatment of unresectable or advanced microsatellite stabilized (MSS/pMMR) colorectal cancer with liver metastases

NCT ID: NCT06149923 Not yet recruiting - Gastric Cancer Clinical Trials

Association Between ABO Polymorphism and Gastric/Colorectal Cancers

Start date: December 1, 2023
Phase:
Study type: Observational

To assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/or colorectal cancers relative to healthy controls by real time PCR.

NCT ID: NCT05709899 Not yet recruiting - Colo-rectal Cancer Clinical Trials

Comparison of Ultrasound-guided Erector Spinae Plane Block and Transmuscular Quadratus Lumborum Block

Start date: August 30, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to compare the postoperative analgesic effect of bupivacaine injection via ultrasound-guided erector spinae block versus transmuscular quadratus lumborum block in patients undergoing abdominal cancer surgery

NCT ID: NCT04073680 Not yet recruiting - Breast Cancer Clinical Trials

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Start date: September 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to test the hypothesis that combining serabelisib, a PI3K alpha isoform inhibitor, with an SGLT2 inhibitor, canagliflozin will improve efficacy in the treatment of patients with advanced solid tumors.

NCT ID: NCT03849352 Not yet recruiting - Colo-rectal Cancer Clinical Trials

Lifestyle Changes Using Digital Technology in Colorectal Cancer

Start date: March 18, 2019
Phase: N/A
Study type: Interventional

The objective of this small study is to assess the feasibility of remotely delivering a diet and lifestyle intervention following treatment of CRC through telecommunications and digital technology. A DBCI will be implemented among a population of people living with and beyond CRC to help identify if patients find this an easy and achievable way to communicate with a Registered Dietitian. The information gained from this small scale feasibility will be used to help develop a larger study on supporting people with CRC to make a lifestyle change.

NCT ID: NCT03618329 Not yet recruiting - Colo-rectal Cancer Clinical Trials

Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM.

PRERAS
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The implementation of prehabilitation in patients operated on for colon cancer in a multimodal rehabilitation regimen improves the values of the "lean body mass" or lean mass index, positively influencing the results of clinical, analytical and radiological nutritional values pre- and postoperatively and in morbi-mortality, recovery, average stay and re-entry rates.

NCT ID: NCT03572595 Not yet recruiting - Recurrence Clinical Trials

F-18 FDG- PETCT in Staging and Recurrent Colorectal Cancer

Start date: July 1, 2018
Phase:
Study type: Observational

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. The overall relative 5-year survival is about 50%-60% but is highly dependent on disease stage at the time of diagnosis ranging from approximately 80% to only 3%. Curative treatment comprises resection of the primary tumour combined with adjuvant chemotherapy in selected patients. In recent years there has been an increasing role for curative intended surgical or ablative intervention in limited metastatic disease, i.e., solitary or few metastases to the liver and/or the lungs. Accurate preoperative staging is of paramount importance for directing the most appropriate therapeutic options, for indicating prognosis and outcome, and to avoid futile operations.

NCT ID: NCT03448302 Not yet recruiting - Colo-rectal Cancer Clinical Trials

Computed Tomography Perfusion Colorectal Cancer With Tumor Grade

Start date: March 10, 2018
Phase: N/A
Study type: Observational

Colorectal cancer is the third most commonly diagnosed cancer in the world. The 5-years survival rate depends on the tumor stage and grade at patient presentation. Individual treatment strategy based on the tumor stage and grade should be applied to improve the prognosis, So the pre-operative diagnostic evaluation and grading of colorectal cancer are important.